Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow C4 Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for C4 Therapeutics, Inc.

CCCC

C4 Therapeutics, Inc.

About C4 Therapeutics, Inc.

C4 Therapeutics is a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) to develop small-molecule medicines that eliminate disease-causing proteins. Leveraging its proprietary TORPEDO platform, the company designs oral, selective protein degraders primarily for oncology indications, including multiple myeloma, non-Hodgkin lymphoma, melanoma, colorectal, and non-small cell lung cancers. C4’s approach offers catalytic, durable, and highly selective therapies addressing unmet medical needs through innovative drug discovery and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from C4 Therapeutics, Inc.

1
1
C4 Therapeutics, Inc. C4 Therapeutics Reports Q1 2026 Financial Results with $6.2M Revenue and $25.1M Net Loss

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
C4 Therapeutics, Inc. C4 Therapeutics Reports $105M Net Loss and $35.9M Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
C4 Therapeutics, Inc. C4 Therapeutics Reports Revenue Decline and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
C4 Therapeutics, Inc. C4 Therapeutics Reports $26M Net Loss in Q2 2025, Revenue Declines

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
C4 Therapeutics, Inc. C4 Therapeutics Reports $7.2 Million Revenue in Q1 2025, Net Loss of $26.3 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
C4 Therapeutics, Inc. C4 Therapeutics Reports Improved Financials, Net Loss of $70.7M for Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments